Lumakras Sotorasib KRAS G12C Targeting NSCLC Review 2026
Author: Critical Kare PharmaThoracic Oncology Desk
On October 19, 2026, medical oncology congresses reviewed updated evidence for Lumakras® (Sotorasib 120 mg and 320 mg film-coated tablets) developed by Amgen as the pioneering first-in-class KRAS G12C covalent inhibitor.
Lumakras irreversibly locks mutant KRAS G12C in its inactive GDP-bound conformation, shattering decades of belief that oncogenic KRAS is an 'undruggable' target and establishing targeted therapy for KRAS-mutated non-small cell lung cancer.
Through Critical Kare Pharma, certified genuine packs of Lumakras Sotorasib Tablets are supplied directly to tertiary cancer centers and named patients globally.
The CodeBreaK 200 Phase 3 Clinical Outcomes
- Progression-Free Advantage: Sotorasib demonstrated statistically significant improvement in 1-year progression-free survival compared to docetaxel in previously treated KRAS G12C-mutated NSCLC.
- Quality of Life Benefit: Substantially lower rates of Grade ≥3 toxicities and superior patient-reported physical functioning compared to intravenous chemotherapy.
- Dosing: Standard dosage is 960 mg orally once daily (eight 120 mg tablets or three 320 mg tablets) taken with or without food.
Global Sourcing via Critical Kare Pharma
Supplied in original tamper-evident cartons with verifiable Certificates of Analysis under international personal import frameworks.
